280 related articles for article (PubMed ID: 33853673)
21. Oncogenic Gene Fusion FGFR3-TACC3 Is Regulated by Tyrosine Phosphorylation.
Nelson KN; Meyer AN; Siari A; Campos AR; Motamedchaboki K; Donoghue DJ
Mol Cancer Res; 2016 May; 14(5):458-69. PubMed ID: 26869289
[TBL] [Abstract][Full Text] [Related]
22. Multiple functions of a glioblastoma fusion oncogene.
Babic I; Mischel PS
J Clin Invest; 2013 Feb; 123(2):548-51. PubMed ID: 23298839
[TBL] [Abstract][Full Text] [Related]
23. Varied histomorphology and clinical outcomes of FGFR3-TACC3 fusion gliomas.
McDonald MF; Athukuri P; Anand A; Gopakumar S; Jalali A; Patel AJ; Rao G; Goodman JC; Lu HC; Mandel JJ
Neurosurg Focus; 2022 Dec; 53(6):E16. PubMed ID: 36455273
[TBL] [Abstract][Full Text] [Related]
24. FGFR1-4 RNA-Based Gene Alteration and Expression Analysis in Squamous Non-Small Cell Lung Cancer.
Moes-Sosnowska J; Skupinska M; Lechowicz U; Szczepulska-Wojcik E; Skronska P; Rozy A; Stepniewska A; Langfort R; Rudzinski P; Orlowski T; Popiel D; Stanczak A; Wieczorek M; Chorostowska-Wynimko J
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142417
[TBL] [Abstract][Full Text] [Related]
25. Glioblastomas harboring gene fusions detected by next-generation sequencing.
Woo HY; Na K; Yoo J; Chang JH; Park YN; Shim HS; Kim SH
Brain Tumor Pathol; 2020 Oct; 37(4):136-144. PubMed ID: 32761533
[TBL] [Abstract][Full Text] [Related]
26. Acquired resistance to LY2874455 in FGFR2-amplified gastric cancer through an emergence of novel FGFR2-ACSL5 fusion.
Kim SY; Ahn T; Bang H; Ham JS; Kim J; Kim ST; Jang J; Shim M; Kang SY; Park SH; Min BH; Lee H; Kang WK; Kim KM; Park W; Lee J
Oncotarget; 2017 Feb; 8(9):15014-15022. PubMed ID: 28122360
[TBL] [Abstract][Full Text] [Related]
27. Discovery of KIN-3248, An Irreversible, Next Generation FGFR Inhibitor for the Treatment of Advanced Tumors Harboring FGFR2 and/or FGFR3 Gene Alterations.
Tyhonas JS; Arnold LD; Cox JM; Franovic A; Gardiner E; Grandinetti K; Kania R; Kanouni T; Lardy M; Li C; Martin ES; Miller N; Mohan A; Murphy EA; Perez M; Soroceanu L; Timple N; Uryu S; Womble S; Kaldor SW
J Med Chem; 2024 Feb; 67(3):1734-1746. PubMed ID: 38267212
[TBL] [Abstract][Full Text] [Related]
28. Recurrent FGFR3-TACC3 fusion gene in nasopharyngeal carcinoma.
Yuan L; Liu ZH; Lin ZR; Xu LH; Zhong Q; Zeng MS
Cancer Biol Ther; 2014; 15(12):1613-21. PubMed ID: 25535896
[TBL] [Abstract][Full Text] [Related]
29. Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma.
Borad MJ; Champion MD; Egan JB; Liang WS; Fonseca R; Bryce AH; McCullough AE; Barrett MT; Hunt K; Patel MD; Young SW; Collins JM; Silva AC; Condjella RM; Block M; McWilliams RR; Lazaridis KN; Klee EW; Bible KC; Harris P; Oliver GR; Bhavsar JD; Nair AA; Middha S; Asmann Y; Kocher JP; Schahl K; Kipp BR; Barr Fritcher EG; Baker A; Aldrich J; Kurdoglu A; Izatt T; Christoforides A; Cherni I; Nasser S; Reiman R; Phillips L; McDonald J; Adkins J; Mastrian SD; Placek P; Watanabe AT; Lobello J; Han H; Von Hoff D; Craig DW; Stewart AK; Carpten JD
PLoS Genet; 2014 Feb; 10(2):e1004135. PubMed ID: 24550739
[TBL] [Abstract][Full Text] [Related]
30. FGFR3, as a receptor tyrosine kinase, is associated with differentiated biological functions and improved survival of glioma patients.
Wang Z; Zhang C; Sun L; Liang J; Liu X; Li G; Yao K; Zhang W; Jiang T
Oncotarget; 2016 Dec; 7(51):84587-84593. PubMed ID: 27829236
[TBL] [Abstract][Full Text] [Related]
31. Impact of fibroblast growth factor receptor 1 (FGFR1) amplification on the prognosis of breast cancer patients.
Erber R; Rübner M; Davenport S; Hauke S; Beckmann MW; Hartmann A; Häberle L; Gass P; Press MF; Fasching PA
Breast Cancer Res Treat; 2020 Nov; 184(2):311-324. PubMed ID: 32852708
[TBL] [Abstract][Full Text] [Related]
32. Fibroblast growth factor receptor (FGFR) alterations in squamous differentiated bladder cancer: a putative therapeutic target for a small subgroup.
Baldia PH; Maurer A; Heide T; Rose M; Stoehr R; Hartmann A; Williams SV; Knowles MA; Knuechel R; Gaisa NT
Oncotarget; 2016 Nov; 7(44):71429-71439. PubMed ID: 27669755
[TBL] [Abstract][Full Text] [Related]
33. Precise editing of FGFR3-TACC3 fusion genes with CRISPR-Cas13a in glioblastoma.
Wu Y; Jin W; Wang Q; Zhou J; Wang Y; Tan Y; Cui X; Tong F; Yang E; Wang J; Kang C
Mol Ther; 2021 Nov; 29(11):3305-3318. PubMed ID: 34274537
[TBL] [Abstract][Full Text] [Related]
34. Targetable Gene Fusions Associate With the IDH Wild-Type Astrocytic Lineage in Adult Gliomas.
Ferguson SD; Zhou S; Huse JT; de Groot JF; Xiu J; Subramaniam DS; Mehta S; Gatalica Z; Swensen J; Sanai N; Spetzler D; Heimberger AB
J Neuropathol Exp Neurol; 2018 Jun; 77(6):437-442. PubMed ID: 29718398
[TBL] [Abstract][Full Text] [Related]
35. Effects of FGFR Signaling on Cell Proliferation and Differentiation of Apert Dental Cells.
Lu C; Huguley S; Cui C; Cabaniss LB; Waite PD; Sarver DM; Mamaeva OA; MacDougall M
Cells Tissues Organs; 2016; 201(1):26-37. PubMed ID: 26613250
[TBL] [Abstract][Full Text] [Related]
36. A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring
Voss MH; Hierro C; Heist RS; Cleary JM; Meric-Bernstam F; Tabernero J; Janku F; Gandhi L; Iafrate AJ; Borger DR; Ishii N; Hu Y; Kirpicheva Y; Nicolas-Metral V; Pokorska-Bocci A; Vaslin Chessex A; Zanna C; Flaherty KT; Baselga J
Clin Cancer Res; 2019 May; 25(9):2699-2707. PubMed ID: 30745300
[TBL] [Abstract][Full Text] [Related]
37. Novel therapeutic strategy for cervical cancer harboring FGFR3-TACC3 fusions.
Tamura R; Yoshihara K; Saito T; Ishimura R; Martínez-Ledesma JE; Xin H; Ishiguro T; Mori Y; Yamawaki K; Suda K; Sato S; Itamochi H; Motoyama T; Aoki Y; Okuda S; Casingal CR; Nakaoka H; Inoue I; Verhaak RGW; Komatsu M; Enomoto T
Oncogenesis; 2018 Jan; 7(1):4. PubMed ID: 29358619
[TBL] [Abstract][Full Text] [Related]
38. Estimation of Percentage of Patients With Fibroblast Growth Factor Receptor Alterations Eligible for Off-label Use of Erdafitinib.
de Almeida Carvalho LM; de Oliveira Sapori Avelar S; Haslam A; Gill J; Prasad V
JAMA Netw Open; 2019 Nov; 2(11):e1916091. PubMed ID: 31755953
[TBL] [Abstract][Full Text] [Related]
39. Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma.
Liao RG; Jung J; Tchaicha J; Wilkerson MD; Sivachenko A; Beauchamp EM; Liu Q; Pugh TJ; Pedamallu CS; Hayes DN; Gray NS; Getz G; Wong KK; Haddad RI; Meyerson M; Hammerman PS
Cancer Res; 2013 Aug; 73(16):5195-205. PubMed ID: 23786770
[TBL] [Abstract][Full Text] [Related]
40. FGFR gene alterations in lung squamous cell carcinoma are potential targets for the multikinase inhibitor nintedanib.
Hibi M; Kaneda H; Tanizaki J; Sakai K; Togashi Y; Terashima M; De Velasco MA; Fujita Y; Banno E; Nakamura Y; Takeda M; Ito A; Mitsudomi T; Nakagawa K; Okamoto I; Nishio K
Cancer Sci; 2016 Nov; 107(11):1667-1676. PubMed ID: 27581340
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
